Expert Interview
Examining the potential of Lilly's GIP/GLP-1/Glucagon Receptor Tri-agonist, retatrutide with a focus on the Phase 2 results in obesity presented at the ADA 2023 Conference
Ticker(s): LLYInstitution: WUSTL
- Associate Professor of Endocrinology, Metabolism & Lipid Research at Washington University in St. Louis
- Treats about 60 patients per month for T2D and obesity
- Clinical specialty in Thyroid disease, diabetes, pituitary disease, osteoporosis (brittle bones), parathyroid disease, high triglycerides, adrenal disease, high cholesterol, gonadal, low high-density lipoprotein cholesterol (HDL), and pancreatic islet disorders.
Roughly how many of your patients are currently on a GIP/GLP-1 agonist?
Added By: sara_adminDo you believe there is a need for a Tri-agonist in this space?
Added By: sara_adminHow would you rate your level of excitement on a scale from 1 - 10, about Retatrutide for patients with obesity, T2D, or NASH?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
